Targeted Cancer Therapy Connect

: Targeted Cancer Therapy Connect Home

Articles

Aims and Scope

Editorial Board

Author's Instructions

Special Issue Guidelines

Abstracting and Indexing

Early Career Researchers

Special Issues

Insights

News

Open Access Policy:
All articles published in the journal Targeted Cancer Therapy Connect are made accessible through an open-access model, released under the Creative Commons Attribution 4.0 (CC BY 4.0) license. This license facilitates the unrestricted dissemination of articles, encouraging widespread sharing and utilization of valuable research contributions.

Publication Charges:
There will be no article processing charges (APCs) for submissions made by March 31, 2026, and all articles will be available as Open Access.

Subject Categories:
Targeted Cancer Therapy, Immunotherapy, Precision Oncology

Article Template:

You are encouraged to use the template to format your article according to our guidelines. However, this is not mandatory, as our layout team will ensure all necessary adjustments are made after acceptance and prior to final publication.

Download Template

Target Audience:
Targeted Cancer Therapy Connect provides a platform for researchers, clinicians, and industry experts to share insights, foster collaboration, and explore emerging directions in targeted and immune-based cancer treatment.

Ethics Statement:

All articles published by Targeted Cancer Therapy Connect adhere strictly to the ethical guidelines suggested by the Committee on Publication Ethics (COPE). We execute a stringent peer-review procedure that meticulously assesses the originality, quality, and precision of the research we disseminate. We employ advanced tools to scrutinize the legitimacy of submitted content and maintain a firm zero-tolerance stance toward instances of plagiarism, data manipulation, or inappropriate authorship. For further details, please review our comprehensive Publication Ethics and Integrity Guidelines.

Insights

More Insights

31 Days

Time to First Peer Review Decision

52 Days

Time to Final Acceptance

7 Days

Acceptance to First Online

Recent Updates

All Updates

Welcoming Dr. Eyad Elkord to Cancer Immunology Connect

2024-08-19

Announcing the Launch of Cancer Immunology Connect

2024-08-15

Recent Articles

All Articles

Mini-Review

Available Online: 23 Dec 2025

Covalent BH3-Mimetics and PROTACs Targeting BCL2 Family for Precision Apoptosis Induction

Volume 1

Abinash Nayak

Abinash Nayak
abinashnayakzoology@gmail.com

The BCL2 family of proteins serves as a central regulator of mitochondrial outer membrane permeabilization (MOMP) and intrinsic apoptosis, with anti-apoptotic members such as BCL2, BCL-XL, and MCL1 frequently overexpressed in cancers to evade programmed cell death. Traditional BH3 mimetics, like venetoclax and navitoclax, have revolutionized treatment for hematologic malignancies by competitively inhibiting these pro-survival proteins, yet they face challenges..